Breaking news and analysis from time.com. Politics, world news, photos, video, tech reviews, health, science, and ...

A new daily pill called daraxonrasib is showing promise against advanced pancreatic cancer in a first-in-human trial of 168 patients with RAS mutations.

Following the mid-stage readout, Verastem Oncology has decided to move away from its investigational pancreatic cancer drug ...

Daraxonrasib doubles survival — a RAS‑targeting drug development breakthrough.

Short-Term Surgical Mission in Sub-Saharan Country, Experience of a Breast-Dedicated Team: Reviewing the Past and Stepping Toward the Last Mission Rapidly expanding systemic treatment options, ...

Cancer drug development has never moved faster. Yet, for too many patients, the next treatment decision still begins with ...

MultiValent Biotherapies, Inc. (MultiValent), a private biotechnology company developing targeted drug conjugate therapies for cancer, announced a $27.425 million first closing of its Series A ...

Enhancing Readability of Lay Abstracts and Summaries for Urologic Oncology Literature Using Generative Artificial Intelligence: BRIDGE-AI 6 Randomized Controlled Trial We trained and tested ML systems ...

Could the next big cancer drug come from global health research? - COMMENT: The next blockbuster treatment drug might not, in fact, come from research into cancer itself but from research into a ...

Share on Pinterest Scientists are looking at the effects of the keto diet on cancer therapies. Dulin/Getty Images A ketogenic diet can interact with certain cancer therapies to block the development ...